Vela Diagnostics has launched new focused (60 genes) and comprehensive (525 genes) next-generation sequencing (NGS)-based panels to detect RNA and DNA cancer biomarkers from formalin-fixed paraffin-embedded (FFPE) tissue specimens.
The new pan-cancer gene panels include the focused OncoKey SL 60 Plus Panel and comprehensive OncoKey SL 525 Plus Panel.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
They can detect insertions/deletions (INDELs), copy number variations (CNVs), single nucleotide variations (SNVs), fusions, splice variants, microsatellite instability (MSI), oncogenic viruses and bacteria in a single assay.
Featuring a sample-to-result workflow, the new NGS-based panels can evaluate up to 64 samples in a single sequencing run.
They require 2.5 hours of hands-on time and generate results within five days.
Vela Diagnostics CEO and executive chairman Sam Dajani said: “Vela Diagnostics is planning to launch our OncoKey 60 and 525 Plus Panels in Q4 2022 in the USA and Asia Pacific.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“Using these panels on Vela Diagnostics’ automated workflow will reduce human error and minimise sample cross-contamination, which can be generated by using a manual workflow.
“In addition, our VELA Analytics solutions and services can identify and interpret genetic variants in tumours, making it possible to provide actionable options for healthcare and research professionals quickly and accurately.”
The company noted that the OncoKey SL 60 and 525 Plus Panels provide high sample traceability, from automated sample extraction to data quality control (QC).
They can be adapted to current lab situations and their workflow is wrapped around Illumina sequencing platforms.
Last November, the US Food and Drug Administration (FDA) granted emergency use authorisation (EUA) to Vela Diagnostics’ ViroKey SARS-CoV-2 reverse transcription-polymerase chain reaction Test v2.0 with expanded automation options.
